

[290] AYALA PHARMACEUTICALS

Roni Mamluk¹, ¹ Ayala Pharmaceuticals

- **Investment Rational**

Ayala is a clinical stage precision oncology company dedicated to developing targeted therapies for genomically-defined, clinically underserved cancers. In 2017, we entered into an exclusive worldwide license agreement to develop and commercialize Bristol-Myers Squibb's best in class NOTCH inhibitor for the treatment of cancers with Notch activation. Our lead program will begin Phase 2 in 2018.
- **Business Strategy**

Ayala's business strategy is to license, develop, commercialize and/or partner unique targeted therapies for cancers that are underserved by available treatment options. We focus on cancers where our products can make the greatest impact on patients, caregivers and healthcare providers.
- **Core Technology**

AL101 is a pan-Notch inhibitor that has shown low nM inhibitory activity and robust, broad-spectrum efficacy in preclinical models. In phase 1b studies, AL101 was well tolerated and demonstrated remarkable PK/PD with sustained Notch inhibition and tolerable side effects in 205 patients. Furthermore, AL101 demonstrated anti-tumor activity in an unselected patient population of advanced metastatic solid tumors and in T-ALL/TLL.
- **Product Profile/Pipeline**

We plan to initiate an open label, single arm phase 2 study with AL101 for recurrent or metastatic Adenoid Cystic Carcinoma (ACC) patients harboring activation of the Notch signaling pathway in 2018. AL101 is also undergoing preclinical testing in patient-derived xenograft (PDX) models for triple negative breast cancer (TNBC).
- **What's Next?**

Ayala closed a Series A financing led by the Israel Biotech Fund and syndicated with aMoon and Harel Insurance. BMS joined as a shareholder. AL101 near-term milestones are preclinical results in PDX models for TNBC and initial results from a phase 2 ACC, open label. In parallel, the company is actively exploring in-licensing opportunities of targeted therapy oncology assets.